Pharmaceuticals News

The pharmaceuticals news email from Wiser has been specifically designed for anyone with an interest in the industry. This includes medical practitioners, investors and those involved in research and development. By its very nature, the pharmaceutical industry is subject to constant change. It is a research-driven industry with companies spending much of their revenues developing new medicines and vaccines. As a result patients are able to get new and more effective treatments. This is helping to increase the life expectancy of individuals in most countries. But there are challenges. The costs of the research and development can be large which puts up the price of drugs, while governments and the medical industry argue to try to keep prices as low as possible. The industry also faces challenges from alternatives, both legal (through generic drugs) and illegal (through black market economies). To follow the latest developments in this industry you should sign up for the pharmaceuticals news email from Wiser. It is the best way to find must-read articles on the topic from around the web.

Recent Pharmaceuticals News Coverage
 
Your Weekly Recommendations Monday, July 24, 2017
 
Recommended for you
What A 24-Year-Old Entrepreneur Can Teach You About Doing Business Globally
Forbes • Contributor, Jessica Pliska
Prescribing Barriers in Psoriasis
MedPage Today • Lisette Hilton
Week In Review: C-Bridge Raises $400 Million For Second China Healthcare Fund
Seeking Alpha • Chinabio Today
The Reasons Why Spectral Medical's Sepsis Treatment Will Not Receive An FDA Approval
Seeking Alpha • The Biochemist
Amgen And Novartis: First Mover Advantage Is A Must
Seeking Alpha • Long Term Bio
3 Things In Biotech You Should Learn Today: July 22, 2017
Seeking Alpha • Zach Hartman
India is like a pregnant woman, still going through labour pains: Ravi Dharamshi, ValueQuest
The Economic Times of India
Three reasons why substituting real world data for certain randomized clinical trials is inevitable
Becker's Hospital Review
Friday Feedback: Why Does Pharma Love Cancer So Much?
MedPage Today
Our Dogs Can Get Lyme Vaccines And We (Still) Can't. When Might We?
WBUR • Commonhealth
 
Recommended for You
Merck & Co., Inc., Pharmaceuticals
What A 24-Year-Old Entrepreneur Can Teach You About Doing Business Globally
ForbesContributor, Jessica Pliska
I first met Y-Lan Nguyen when she was a 16-year-old high school student who joined my organization, the Opportunity Network. I recently asked her how she built a global business and what she learned in the process. Y-Lan has been part of...
Share
Biotechnology, Health Care Industry
Prescribing Barriers in Psoriasis
MedPage TodayLisette Hilton
In February, the FDA approved brodalumab (Siliq, from Valeant Pharmaceuticals) for adults with moderate-to-severe plaque psoriasis. The injectable biologic shines for its impact on the disease. In one phase III study published in 2015 in the New England Journal of Medicine, researchers...
Share
Cancer, Finance
Week In Review: C-Bridge Raises $400 Million For Second China Healthcare Fund
Seeking AlphaChinabio Today
Deals and Financings C-Bridge Capital, a China private equity firm with a life science focus, closed its second fund, C-Bridge Healthcare Fund II, at its $400 million cap. C-Bridge plans to invest in late-stage companies in the fields of biotechnology, pharmaceuticals, medical...
Share
Epidemiology, Pharmaceuticals
The Reasons Why Spectral Medical's Sepsis Treatment Will Not Receive An FDA Approval
Seeking AlphaThe Biochemist
Summary Spectral’s trial failed to meet its stated primary end point. Further analysis failed to identify any reason for the trial’s failure. Spectral's sepsis treatment deals with only one factor, of questionable importance, in a highly complex medical condition. More than 100...
Share
Health Finance, Novartis AG
Amgen And Novartis: First Mover Advantage Is A Must
Seeking AlphaLong Term Bio
Summary Two Phase 3 clinical trials make the case for erenumab to be approved by the FDA on May 17 The competitive nature of the CGRP drug migraine space is fierce with many other compounds in phase 3 trials The market opportunity...
Share
Cancer, Epidemiology
3 Things In Biotech You Should Learn Today: July 22, 2017
Seeking AlphaZach Hartman
Summary Merck grabs approval in Europe for bladder cancer drug. Incyte marches on in GVHD. The FDA accepts CSL Limited's new drug application in neurologic disorders. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest...
Share
Pharmaceuticals
India is like a pregnant woman, still going through labour pains: Ravi Dharamshi, ValueQuest
The Economic Times of India
In an exclusive interview with Nikunj Dalmia of ET Now, Ravi Dharamshi, CIO, ValueQuest Investment , says India's good macros have been punctuated by some real long term changes that our society and business environment has been undergoing -- demonetisation and GST....
Share
Electronic Health Records, Epidemiology
Three reasons why substituting real world data for certain randomized clinical trials is inevitable
Becker's Hospital Review
The 21st Century Cures Act and planned Prescription Drug User Fee Act (PDUFA) VI are changing the regulatory environment and accelerating the rate at which evidence generated from real world data (RWD) is incorporated into regulatory decision-making. The Network for Excellence in...
Share
Health Care Industry, Pharmaceuticals
Friday Feedback: Why Does Pharma Love Cancer So Much?
MedPage Today
(MedPage Today) -- Experts debate clinical versus profit-driven priorities in drug development
Share
Epidemiology, GlaxoSmithKline plc
Our Dogs Can Get Lyme Vaccines And We (Still) Can't. When Might We?
WBURCommonhealth
Part of our Losing to Lyme series For Dr. Stanley Plotkin, a prominent vaccine scientist, Lyme disease is personal. His son, Alec, collapsed from a slow heart rate when he was 39, brought down by a rare heart complication from Lyme. His...
Share